Clinical Characteristics and Outcome in Dogs with Splenic Marginal Zone Lymphoma

D. O'Brien, Peter F Moore, William Vernau, J. R. Peauroi, Robert B Rebhun, C. O. Rodriguez, Katherine A Skorupski

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Splenic marginal zone lymphoma (MZL) is a form of indolent B-cell lymphoma that is not well characterized in dogs. Hypothesis/Objectives: The purpose of this study was to describe clinical characteristics and outcome in dogs with splenic MZL confirmed by histopathology, immunophenotyping, and molecular clonality assessment. We hypothesized that affected dogs would have prolonged survival time with splenectomy alone. Animals: Thirty-four dogs were included. Twenty-nine dogs were diagnosed after splenectomy, and 5 dogs were diagnosed at necropsy. Methods: Pathology records were searched for dogs with histologically confirmed splenic MZL. Clinical and outcome data were retrospectively collected by medical record review, and prognostic factors were evaluated. Histopathology was reviewed by a board-certified pathologist, and tissue sections were subjected to immunophenotyping and molecular clonality assessment by PCR. Results: Immunohistochemistry confirmed a B-cell phenotype for all dogs. Molecular clonality assessment was performed in 33 of 34 dogs, of which 24 had clonal rearrangement of immunoglobulin (Ig) loci, 3 had pseudoclonal rearrangement, and 6 had polyclonal rearrangement. The overall median survival time (MST) for the 29 dogs that underwent splenectomy was 383 days. The MST for 14 of 29 asymptomatic dogs that underwent splenectomy for MZL was 1,153 days as compared to 309 days for 15/29 dogs with clinical signs referable to splenic MZL (P = .018). Lymph node involvement, hemoabdomen, anemia, chemotherapy, and concurrent malignancy did not affect survival outcome. Conclusions and Clinical Importance: Dogs diagnosed with splenic MZL can have prolonged survival with splenectomy alone, without the use of adjuvant chemotherapy. Asymptomatic dogs may have a better survival outcome.

Original languageEnglish (US)
Pages (from-to)949-954
Number of pages6
JournalJournal of Veterinary Internal Medicine
Volume27
Issue number4
DOIs
StatePublished - Jul 2013

Fingerprint

lymphoma
Lymphoma
Dogs
dogs
Splenectomy
Immunophenotyping
histopathology
drug therapy
B-lymphocytes
B-Cell Lymphoma
Adjuvant Chemotherapy
anemia
immunoglobulins
adjuvants
Medical Records
immunohistochemistry
lymph nodes
Immunoglobulins
Anemia
necropsy

Keywords

  • Canine
  • Indolent lymphoma
  • Neoplasia

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Clinical Characteristics and Outcome in Dogs with Splenic Marginal Zone Lymphoma. / O'Brien, D.; Moore, Peter F; Vernau, William; Peauroi, J. R.; Rebhun, Robert B; Rodriguez, C. O.; Skorupski, Katherine A.

In: Journal of Veterinary Internal Medicine, Vol. 27, No. 4, 07.2013, p. 949-954.

Research output: Contribution to journalArticle

@article{cc96ecadcaa045229709be6f5bb3636d,
title = "Clinical Characteristics and Outcome in Dogs with Splenic Marginal Zone Lymphoma",
abstract = "Background: Splenic marginal zone lymphoma (MZL) is a form of indolent B-cell lymphoma that is not well characterized in dogs. Hypothesis/Objectives: The purpose of this study was to describe clinical characteristics and outcome in dogs with splenic MZL confirmed by histopathology, immunophenotyping, and molecular clonality assessment. We hypothesized that affected dogs would have prolonged survival time with splenectomy alone. Animals: Thirty-four dogs were included. Twenty-nine dogs were diagnosed after splenectomy, and 5 dogs were diagnosed at necropsy. Methods: Pathology records were searched for dogs with histologically confirmed splenic MZL. Clinical and outcome data were retrospectively collected by medical record review, and prognostic factors were evaluated. Histopathology was reviewed by a board-certified pathologist, and tissue sections were subjected to immunophenotyping and molecular clonality assessment by PCR. Results: Immunohistochemistry confirmed a B-cell phenotype for all dogs. Molecular clonality assessment was performed in 33 of 34 dogs, of which 24 had clonal rearrangement of immunoglobulin (Ig) loci, 3 had pseudoclonal rearrangement, and 6 had polyclonal rearrangement. The overall median survival time (MST) for the 29 dogs that underwent splenectomy was 383 days. The MST for 14 of 29 asymptomatic dogs that underwent splenectomy for MZL was 1,153 days as compared to 309 days for 15/29 dogs with clinical signs referable to splenic MZL (P = .018). Lymph node involvement, hemoabdomen, anemia, chemotherapy, and concurrent malignancy did not affect survival outcome. Conclusions and Clinical Importance: Dogs diagnosed with splenic MZL can have prolonged survival with splenectomy alone, without the use of adjuvant chemotherapy. Asymptomatic dogs may have a better survival outcome.",
keywords = "Canine, Indolent lymphoma, Neoplasia",
author = "D. O'Brien and Moore, {Peter F} and William Vernau and Peauroi, {J. R.} and Rebhun, {Robert B} and Rodriguez, {C. O.} and Skorupski, {Katherine A}",
year = "2013",
month = "7",
doi = "10.1111/jvim.12116",
language = "English (US)",
volume = "27",
pages = "949--954",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Clinical Characteristics and Outcome in Dogs with Splenic Marginal Zone Lymphoma

AU - O'Brien, D.

AU - Moore, Peter F

AU - Vernau, William

AU - Peauroi, J. R.

AU - Rebhun, Robert B

AU - Rodriguez, C. O.

AU - Skorupski, Katherine A

PY - 2013/7

Y1 - 2013/7

N2 - Background: Splenic marginal zone lymphoma (MZL) is a form of indolent B-cell lymphoma that is not well characterized in dogs. Hypothesis/Objectives: The purpose of this study was to describe clinical characteristics and outcome in dogs with splenic MZL confirmed by histopathology, immunophenotyping, and molecular clonality assessment. We hypothesized that affected dogs would have prolonged survival time with splenectomy alone. Animals: Thirty-four dogs were included. Twenty-nine dogs were diagnosed after splenectomy, and 5 dogs were diagnosed at necropsy. Methods: Pathology records were searched for dogs with histologically confirmed splenic MZL. Clinical and outcome data were retrospectively collected by medical record review, and prognostic factors were evaluated. Histopathology was reviewed by a board-certified pathologist, and tissue sections were subjected to immunophenotyping and molecular clonality assessment by PCR. Results: Immunohistochemistry confirmed a B-cell phenotype for all dogs. Molecular clonality assessment was performed in 33 of 34 dogs, of which 24 had clonal rearrangement of immunoglobulin (Ig) loci, 3 had pseudoclonal rearrangement, and 6 had polyclonal rearrangement. The overall median survival time (MST) for the 29 dogs that underwent splenectomy was 383 days. The MST for 14 of 29 asymptomatic dogs that underwent splenectomy for MZL was 1,153 days as compared to 309 days for 15/29 dogs with clinical signs referable to splenic MZL (P = .018). Lymph node involvement, hemoabdomen, anemia, chemotherapy, and concurrent malignancy did not affect survival outcome. Conclusions and Clinical Importance: Dogs diagnosed with splenic MZL can have prolonged survival with splenectomy alone, without the use of adjuvant chemotherapy. Asymptomatic dogs may have a better survival outcome.

AB - Background: Splenic marginal zone lymphoma (MZL) is a form of indolent B-cell lymphoma that is not well characterized in dogs. Hypothesis/Objectives: The purpose of this study was to describe clinical characteristics and outcome in dogs with splenic MZL confirmed by histopathology, immunophenotyping, and molecular clonality assessment. We hypothesized that affected dogs would have prolonged survival time with splenectomy alone. Animals: Thirty-four dogs were included. Twenty-nine dogs were diagnosed after splenectomy, and 5 dogs were diagnosed at necropsy. Methods: Pathology records were searched for dogs with histologically confirmed splenic MZL. Clinical and outcome data were retrospectively collected by medical record review, and prognostic factors were evaluated. Histopathology was reviewed by a board-certified pathologist, and tissue sections were subjected to immunophenotyping and molecular clonality assessment by PCR. Results: Immunohistochemistry confirmed a B-cell phenotype for all dogs. Molecular clonality assessment was performed in 33 of 34 dogs, of which 24 had clonal rearrangement of immunoglobulin (Ig) loci, 3 had pseudoclonal rearrangement, and 6 had polyclonal rearrangement. The overall median survival time (MST) for the 29 dogs that underwent splenectomy was 383 days. The MST for 14 of 29 asymptomatic dogs that underwent splenectomy for MZL was 1,153 days as compared to 309 days for 15/29 dogs with clinical signs referable to splenic MZL (P = .018). Lymph node involvement, hemoabdomen, anemia, chemotherapy, and concurrent malignancy did not affect survival outcome. Conclusions and Clinical Importance: Dogs diagnosed with splenic MZL can have prolonged survival with splenectomy alone, without the use of adjuvant chemotherapy. Asymptomatic dogs may have a better survival outcome.

KW - Canine

KW - Indolent lymphoma

KW - Neoplasia

UR - http://www.scopus.com/inward/record.url?scp=84880507311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880507311&partnerID=8YFLogxK

U2 - 10.1111/jvim.12116

DO - 10.1111/jvim.12116

M3 - Article

VL - 27

SP - 949

EP - 954

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 4

ER -